Description

BioSenic S.A. is a biotechnology firm focused on developing advanced therapeutic solutions. Their innovative technological portfolio includes a state-of-the-art allogeneic cell and gene therapy platform, which utilizes specialized mesenchymal stromal cells sourced from bone marrow that can be conveniently stored at the hospital for immediate application. Additionally, the company is advancing an Arsenic TriOxide platform, which is being explored in immuno-oncology to treat serious conditions such as graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. A significant investigational medicinal product for BioSenic is ALLOB, currently in a Phase IIb clinical trial for patients with complex tibial fractures. The company's operations are based in Mont-Saint-Guibert, Belgium.